• Something wrong with this record ?

Investigation of anti-neuronal antibodies and disparity in central hypersomnias

P. Prochazkova, K. Sonka, R. Roubalova, J. Jezkova, S. Nevsimalova, J. Buskova, R. Merkova, T. Dvorakova, I. Prihodova, S. Dostalova, H. Tlaskalova-Hogenova

. 2024 ; 113 (-) : 220-231. [pub] 20231130

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24007755

STUDY OBJECTIVES: Microbial antigens can elicit an immune response leading to the production of autoantibodies cross-reacting with autoantigens. Still, their clinical significance in human sera in the context of brain diseases is unclear. Therefore, assessment of natural autoantibodies reacting with their neuropeptides may elucidate the autoimmune etiology of central hypersomnias. The study aims to determine whether serum autoantibody levels differ in patients with different types of central hypersomnias (narcolepsy type 1 and 2, NT1 and NT2; idiopathic hypersomnia, IH) and healthy controls and if the differences could suggest the participation of autoantibodies in disease pathogenesis. METHODS: Sera from 91 patients with NT1, 27 with NT2, 46 with IH, and 50 healthy controls were examined for autoantibodies against assorted neuropeptides. Participants were screened using questionnaires related to sleep disorders, quality of life, and mental health conditions. In addition, serum biochemical parameters and biomarkers of microbial penetration through the intestinal wall were determined. RESULTS: A higher prevalence of autoantibodies against neuropeptides was observed only for alpha-melanocytes-stimulating hormone (α-MSH) and neuropeptide glutamic acid-isoleucine (NEI), which differed slightly among diagnoses. Patients with both types of narcolepsy exhibited signs of microbial translocation through the gut barrier. According to the questionnaires, patients diagnosed with NT2 or IH had subjectively worse life quality than patients with NT1. Patients displayed significantly lower levels of bilirubin and creatinine and slightly higher alkaline phosphatase values than healthy controls. CONCLUSIONS: Overall, serum anti-neuronal antibodies prevalence is rare, suggesting that their participation in the pathophysiology of concerned sleep disorders is insignificant. Moreover, their levels vary slightly between diagnoses indicating no major diagnostic significance.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007755
003      
CZ-PrNML
005      
20240423160232.0
007      
ta
008      
240412e20231130ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.sleep.2023.11.039 $2 doi
035    __
$a (PubMed)38056084
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Prochazkova, Petra $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic. Electronic address: kohler@biomed.cas.cz
245    10
$a Investigation of anti-neuronal antibodies and disparity in central hypersomnias / $c P. Prochazkova, K. Sonka, R. Roubalova, J. Jezkova, S. Nevsimalova, J. Buskova, R. Merkova, T. Dvorakova, I. Prihodova, S. Dostalova, H. Tlaskalova-Hogenova
520    9_
$a STUDY OBJECTIVES: Microbial antigens can elicit an immune response leading to the production of autoantibodies cross-reacting with autoantigens. Still, their clinical significance in human sera in the context of brain diseases is unclear. Therefore, assessment of natural autoantibodies reacting with their neuropeptides may elucidate the autoimmune etiology of central hypersomnias. The study aims to determine whether serum autoantibody levels differ in patients with different types of central hypersomnias (narcolepsy type 1 and 2, NT1 and NT2; idiopathic hypersomnia, IH) and healthy controls and if the differences could suggest the participation of autoantibodies in disease pathogenesis. METHODS: Sera from 91 patients with NT1, 27 with NT2, 46 with IH, and 50 healthy controls were examined for autoantibodies against assorted neuropeptides. Participants were screened using questionnaires related to sleep disorders, quality of life, and mental health conditions. In addition, serum biochemical parameters and biomarkers of microbial penetration through the intestinal wall were determined. RESULTS: A higher prevalence of autoantibodies against neuropeptides was observed only for alpha-melanocytes-stimulating hormone (α-MSH) and neuropeptide glutamic acid-isoleucine (NEI), which differed slightly among diagnoses. Patients with both types of narcolepsy exhibited signs of microbial translocation through the gut barrier. According to the questionnaires, patients diagnosed with NT2 or IH had subjectively worse life quality than patients with NT1. Patients displayed significantly lower levels of bilirubin and creatinine and slightly higher alkaline phosphatase values than healthy controls. CONCLUSIONS: Overall, serum anti-neuronal antibodies prevalence is rare, suggesting that their participation in the pathophysiology of concerned sleep disorders is insignificant. Moreover, their levels vary slightly between diagnoses indicating no major diagnostic significance.
650    _2
$a lidé $7 D006801
650    _2
$a kvalita života $7 D011788
650    12
$a poruchy nadměrné spavosti $x epidemiologie $7 D006970
650    12
$a narkolepsie $x epidemiologie $7 D009290
650    12
$a neuropeptidy $7 D009479
650    _2
$a autoprotilátky $7 D001323
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sonka, Karel $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Roubalova, Radka $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Jezkova, Janet $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Nevsimalova, Sona $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Buskova, Jitka $u National Institute of Mental Health, Klecany, Czech Republic; Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Merkova, Radana $u National Institute of Mental Health, Klecany, Czech Republic; Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Dvorakova, Tereza $u National Institute of Mental Health, Klecany, Czech Republic; Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Prihodova, Iva $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Dostalova, Simona $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Tlaskalova-Hogenova, Helena $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
773    0_
$w MED00006025 $t Sleep medicine $x 1878-5506 $g Roč. 113 (20231130), s. 220-231
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38056084 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160228 $b ABA008
999    __
$a ok $b bmc $g 2081627 $s 1217522
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 113 $c - $d 220-231 $e 20231130 $i 1878-5506 $m Sleep medicine $n Sleep Med $x MED00006025
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options